Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

Development Leadership Team in Place to Advance Voreloxin to Late-Stage

Trials Strategic Realignment Includes Workforce Reduction to Streamline Operations

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a corporate realignment to focus on the development of the company's lead oncology product candidate, voreloxin (formerly SNS-595). In conjunction with this strategic restructuring, Sunesis expanded the company's late-stage development leadership team and announced a workforce reduction of approximately 60 percent, including the winding down of its research activities. These changes are intended to concentrate the company's financial and human resources on the strongest path to potential near-term value creation for the company's stockholders.

"Based on the promising clinical data achieved to date, we have made a strategic decision to focus the organization on generating critical clinical data by advancing our lead compound, voreloxin, into late-stage trials in the acute myeloid leukemia and ovarian cancer indications," said Daniel Swisher, Sunesis' Chief Executive Officer. "Late-stage development requires increased focus of our resources. We are also expanding and strengthening our development team with the additions of Drs. Steve Ketchum and Mary Bolton. Their extensive product development and regulatory expertise and track records of successful FDA submissions in a breadth of therapeutic areas will support our plan to advance voreloxin through late-stage trials."

Steven B. Ketchum, Ph.D., has been appointed as Senior Vice President, Research and Development and Mary G. Bolton, M.D., Ph.D., as Vice President,
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., SAN DIEGO, Calif., Dec. 4 Sune...ice company, today announced the appointment of Ph...Officer. In this role, Mr. Ranker will lead all S...ns including finance, accounting, IT, IR, administ... the Company,s senior management team. ,, "One...
(Date:12/4/2009)..., BETHESDA, Md., Dec. 4 Drs. Neal... prostate-specific antigen (PSA) recurrence from t...biochemical recurrence rate in a Phase III pivotal...jection) or monthly leuprolide in prostate cancer ...tate cancer patients who received FIRMAGON 240/80 ...
(Date:12/3/2009)..., ACTON, Mass., Dec. 3 /PRNewswire-FirstCall/ -...Holdings, Inc. (NYSE: HRC ), today announced the... Equipment Manufacturer) business website www.Al...e Allen Amatech(TM) brand identity and includes an...etailed descriptions and design specifications for...
Breaking Medicine Technology:Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic 56522 1Fifteenth US Patent Issued for aTyr Pharma Novel Biotherapeutic 56522 2Arctic Sun Again Preferred Choice of Top Ranked U S Hospitals for Therapeutic Temperature Management 56520 1Arctic Sun Again Preferred Choice of Top Ranked U S Hospitals for Therapeutic Temperature Management 56520 2Arctic Sun Again Preferred Choice of Top Ranked U S Hospitals for Therapeutic Temperature Management 56520 32009 India Excellence in Healthcare Awards 56519 12009 India Excellence in Healthcare Awards 56519 22009 India Excellence in Healthcare Awards 56519 32009 India Excellence in Healthcare Awards 56519 4
...if., Jan. 9 Rigel,Pharmaceuticals, Inc. (Nasdaq: ...g patients in a Phase 1 study to evaluate the safe...potent inhibitor of Janus Kinase,3 (JAK3), as a po...hritis,(RA), psoriasis and other immune disorders....ctive in reducing arthritic symptoms, bone destruc...
...mafore Pharmaceuticals Inc.,today announced that a...,Issue 1: 206-215) reports that SF1126, the compan... antiangiogenic activity., The paper, entitled "A...nhibitor Prodrug, SF1126, with Antitumor and Antia...es conducted by Semafore and collaborators at,Chil...
Other Medicine Technology:Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 2Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders 3Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity 2
(Date:12/5/2009)... Midbrook,s advanced Technology Center helps...es. The technology available to the lab allows it ...ems for customers relating to cleaning parts, proc... (Vocus) December 5, 2009 -- Midbrook,...advanced technology center laboratory that perform...
(Date:12/5/2009)... AVIVA today announced the launch of Interna...private medical insurance plan which follows the a...ddition to offering customers the flexibility to a... needs and budgets, International Solutions enable... those already offered in their country of residen...
(Date:12/5/2009)... The MAMA campaign is a collaborative effort...onal Midwives (NACPM), Midwives Alliance of North ...rnational Center for Traditional Childbearing (ICT...d the Midwifery Education Accreditation Council (M...MA Campaign to secure federal recognition of CPMs ...
(Date:12/5/2009)... Wind Turbines are popping up in the most un...shrooms, making wine to keeping prisoners in jail!...09 -- Who would have thought that your wine, water...? Wind Inc. of Fort Worth, Texas has announced a n...ind farms. "Using a technology developed to provi...
(Date:12/4/2009)... PALO ALTO, Calif., Dec. 4 /PRNewswire-FirstCall/ ... today that its Board of Directors has set the reg...ary 11, 2010 with a record date of December 16, 20...abana Hotel, 4290 El Camino Real, Palo Alto, Calif...ebcast by Thomson Financial and can be accessed at...
Breaking Medicine News(10 mins):Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:Distributor Announces New Applications for Wind Turbines 2Health News:Distributor Announces New Applications for Wind Turbines 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2
...d on findings of a recent study researchers say an...have little effect on // hospitalizations, respira...The finding was especially true for children who r...ected. However, for children under age 2 who recei...
...rding to a recent study researchers say, Monteluka...s mediate inflammation // in the body and play a r... asthma in young children by about 32 percent whil... of the children received low-dose montelukast onc...
...icosteroids, which are routinely used to treat pat...to death, //reports a study conducted at London Sc...esearchers had studied the effect of this drug on ...s. The results showed that there seems to be an in...
...rding to a recent study researchers say those in t...e associated with // an increased risk of suicidal...ents with depression and other clinical conditions...atients taking SSRIs and those taking other drugs,...
...ford Hospital in US is one of the first to impleme...ings of the heart without having to operate.// The... of the patient’s heart. The technology uses an “i... preferences to cardiac surgeons even before they ...
...nt studies have shown that oral examination may no...urbances in patients.// Earlier patients suffe...have mostly been related to snoring in their sleep..., heart problems, stroke, and obesity, breathing p...
Other Medicine News:
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: